Advancing the translation of optical imaging agents for clinical imaging by Sevick-Muraca, Eva M et al.




Advancing the translation of optical imaging agents
for clinical imaging
Eva M. Sevick-Muraca
University of Texas Health Science Center at Houston
Walter J. Akers
Washington University School of Medicine in St. Louis
Bishnu P. Joshi
University of Michigan - Ann Arbor
Gary D. Lurker
University of Michigan - Ann Arbor
Cathy S. Cutler
University of Missouri
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Sevick-Muraca, Eva M.; Akers, Walter J.; Joshi, Bishnu P.; Lurker, Gary D.; Cutler, Cathy S.; Marnett, Lawrence J.; Contag, Christopher
H.; Wang, Thomas D.; and Azhdarinia, Ali, ,"Advancing the translation of optical imaging agents for clinical imaging." Biomedical
Optics Express.4,1. 160-170. (2013).
http://digitalcommons.wustl.edu/open_access_pubs/3551
Authors
Eva M. Sevick-Muraca, Walter J. Akers, Bishnu P. Joshi, Gary D. Lurker, Cathy S. Cutler, Lawrence J. Marnett,
Christopher H. Contag, Thomas D. Wang, and Ali Azhdarinia
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/3551
Advancing the translation of optical imaging 
agents for clinical imaging 
Eva M. Sevick-Muraca,1 Walter J. Akers,2 Bishnu P. Joshi,3 Gary D. Luker,3  
Cathy S. Cutler,4 Lawrence J. Marnett,5 Christopher H. Contag,6 Thomas D. Wang,3 
and Ali Azhdarinia1,* 
1The University of Texas Health Science Center at Houston, Center for Molecular Imaging,  
The Brown Foundation Institute of Molecular Medicine, 1825 Pressler Street, Houston, TX 77030, USA 
2Washington University School of Medicine, Department of Radiology, St. Louis, MO 63110, USA 
3The University of Michigan, School of Medicine, Department of Internal-Medicine-Division of Gastroenterology, 
Ann Arbor, MI 48109, USA 
4University of Missouri Research Reactor Center (MURR), Radiopharmaceutical Sciences Institute,  
Nuclear Engineering and Sciences Institute, Nuclear Engineering, Columbia, MO 65211, USA 
5Vanderbilt University, Department of Chemistry, Nashville, TN 37240, USA 
6Stanford University, School of Medicine, Department of Pediatrics, Stanford, CA 94305, USA 
*ali.azhdarinia@uth.tmc.edu 
Abstract: Despite the development of a large number of promising 
candidates, few contrast agents for established medical imaging modalities 
have successfully been translated over the past decade. The emergence of 
new imaging contrast agents that employ biomedical optics is further 
complicated by the relative infancy of the field and the lack of approved 
imaging devices compared to more established clinical modalities such as 
nuclear medicine. Herein, we propose a navigational approach (as opposed 
to a fixed “roadmap”) for translation of optical imaging agents that is 
(i) proposed through consensus by four academic research programs that are 
part of the cooperative U54 NCI Network for Translational Research, 
(ii) developed through early experiences for translating optical imaging 
agents in order to meet distinctly varied needs in cancer diagnostics, and 
(iii) adaptable to the rapidly changing environment of academic medicine. 
We describe the pathways by which optical imaging agents are synthesized, 
qualified, and validated for preclinical testing, and ultimately translated for 
“first-in-humans” studies using investigational optical imaging devices. By 
identifying and adopting consensus approaches for seemingly disparate 
optical imaging modalities and clinical indications, we seek to establish a 
systematic method for navigating the ever-changing “roadmap” to most 
efficiently arrive at the destination of clinical adoption and improved 
outcome and survivorship for cancer patients. 
© 2012 Optical Society of America 
OCIS codes: (170.0170) Medical optics and biotechnology; (170.3880) Medical and biological 
imaging; (170.3890) Medical optics instrumentation. 
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1. Introduction 
Biomedical optical imaging technologies have substantive potential for revolutionizing cancer 
diagnosis, staging, treatment and survivorship, but translation of these technologies from the 
academic research laboratories into academic medicine is stymied by the lack of a “model” or 
“roadmap”. Since there have been few targeted optical imaging agents that have been 
successfully translated, there is a need to chart the translational pathway. “First-in-humans” 
studies of optical imaging agents are needed for initial demonstration of potential clinical 
utility, but this uncharted territory is further complicated by the lack of appropriate imaging 
instruments that are approved for clinical use. Regulatory pathways that require combinational 
drug (contrast agent) approval from Center for Drug Evaluation and Research (CDER) or 
Center for Biologics Evaluation and Research (CBER), and device approval (imaging 
instrument) from Center for Devices and Radiological Health (CDRH), comprise one of the 
requisite steps in translation that can be more substantial if the synthesis, validation, and 
qualification of an imaging agent is conducted independently from its respective 
investigational imaging device. The Chemistry Probes and Guided Therapies Core working 
group of the NCI Network of Translational Research (NTR) is charged with describing the 
development of optical imaging agents within the context of the diverse translational optical 
imaging projects in each of the NTR Centers (comprised of Stanford University (SU), 
University of Michigan (UM), Washington University at St. Louis (WUSTL), and the 
University of Texas Health Science Center (UTHSC)), and sharing common experiences to 
accelerate the translation of optical imaging agents. The NTR is the second of two consecutive 
programs in the NCI Cancer Imaging portfolio that seeks to translate imaging technologies. In 
its first NCI U54 program (2003-2008), the Network for Translational Optical Imaging 
(NTROI) focused upon translating optical devices while the current NTR (2008-2013) focuses 
upon translating optical imaging devices and imaging agents together with a conventional 
imaging modality to provide embedded validation. 
2. NTR translational projects 
As a means of introduction, Table 1 provides a listing of the device platform/modality, 
proposed imaging agent, and unmet clinical need addressed in each of the NTR projects. Not 
all biomedical optical imaging modalities are presented within the NTR, but all possess the 
translation of a combinational drug/device in some type of hybrid imaging approach that 
could lend further validation through comparative efficacy studies. Initially, each team is 
advancing combinations of contrast agents and instruments for very specific unmet clinical 
needs, however, each set of technologies is designed to have broader clinical utility thereafter 
and are described briefly below. 
SU employs next generation, multi-wavelength, fiber-optic fluorescent micro-endoscopes 
for gastrointestinal screening of high-risk populations. Their technology development targets a 
high-risk population with hereditary diffuse gastric cancer (HDGC), which is an autosomal 
dominant cancer susceptibility syndrome caused by germline mutations in E-cadherin 
(CDH1). Without standard-of-care, prophylactic gastrectomy, subjects with HDGC 
experience an 80% lifetime risk of developing, and dying from, gastric cancer. The 
translational paradigm of SU focuses upon conducting esophagogastroduodenoscopy in these 
patients using wide-field fluorescence endoscopes (macroscopic) and miniaturized dual-axis 
confocal microscopes (microscopic) [1,2] for interrogation of fluorescence following 
intravenous (i.v.) administration of a “first-in-humans” imaging agent, fluorocoxib, that was 
developed in collaboration with Vanderbilt University (VU) to target cyclooxygenase-2 
(COX-2) [3]. The off-label use of indocyanine green (ICG) comprises a first step toward 
translation enabling validation of the microendoscope prior to deploying the COX-2 agent. 
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Table 1. Overview of NTR teams and research strategies 
Research 













• Fluorescently  
   labeled COX-2  
   targeting probes 
Gastrointestinal 
tract cancers 
• Molecularly guided detection   
   of neoplasia in the GI is   
   non-existent 
• Optical imaging at time of   
   visual endoscopy will improve   
   sensitivity of endoscopic   
   detection in high risk cases 
  
UM In Vivo Detection 




   endoscopy 
• Fluorescently  
   labeled peptides 
Colonic 
neoplasia 
• Molecularly guided detection   
   of neoplasia in the colon is   
   non-existent 
• Fluorescence molecular   
   imaging at time of visual   
   endoscopy will improve   
   sensitivity of endoscopic   









• Photoacoustic   
   and diffuse   
   optical   
   tomography 
• Dual-labeled   
   imaging probes 
LN mapping in 
breast cancer 
• PAT techniques offer a high   
   resolution, non-ionizing   
   method for detecting SLNs 
• Ability to combine the   
   sensitivity/specificity of optical   
   imaging with depth and   
   resolution of ultrasound 
  
UTHSC Diagnostic Nodal 
Staging with 
Nuclear and NIR 
Molecular 
Optical Imaging 
• NIRF imaging 
• Dual-labeled   
   imaging probes 
Lymphatic 
imaging and LN 
detection in 
cancer 
•NIR fluorescence provides a   
   rapid method for visualizing   
   the lymphatic function   
   architecture not possible with   
   lymphoscintigraphy 
•Dual-labeled imaging agents   
   targeting cancer in LNs lymph   
   nodes provide non-invasive   
   TNM staging through whole   
   body and intraoperative   
   imaging. 
The translational paradigm at UM involves combination instruments for fluorescent 
colonoscopy in high-risk individuals diagnosed with familial adenomatous polyposis (FAP) 
and hereditary nonpolyposis colorectal cancer (HNCPP, Lynch Syndrome). In their proposed 
“first-in-humans” studies, peptides discovered through phage display technologies are labeled 
with fluorescein isothiocyanate (FITC), a derivative of the green fluorophore, fluorescein, 
which is already used in humans. These are designed for topical administration and to bind to 
luminal intestinal surfaces of dysplastic mucosa to enable early detection and screening in 
high-risk populations [4–6]. 
WUSTL has focused on translation of photoacoustic tomography (PAT) which 
significantly increases the effective depth of optical contrast detection [7]. Pre-operative PAT 
detects uptake of off-label intradermal administration methylene blue (MB) and ICG in order 
to perioperatively identify sentinel lymph nodes (SLNs) in breast cancer patients [8]. Off-label 
use of approved agents accelerates the deployment of the PAT imaging device in human 
studies. Novel multimodal agents are also under development to enable hybrid imaging using 
PAT/fluorescence/nuclear imaging and include (i) a derivative of ICG that can be conjugated 
to a chelating agent for radiometal sequestration, (ii) MB with isotopic Iodine-125 labeling 
[9], and (iii) functionalized nanoparticles for targeted, molecular imaging using PAT, nuclear, 
and fluorescence imaging approaches [10–12]. This multimodal approach provides means for 
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validation of PAT with standard-of-care gamma scintigraphy or Single-Photon Emission 
Computed Tomography (SPECT) for SLN mapping, as well as future molecular imaging 
applications. 
Finally, the UTHSC primary project focuses upon the development of multimodal “first-
in-humans” imaging agents possessing a radiolabel and a near-infrared (NIR) fluorophore to 
permit non-invasive imaging of lymph node (LN) status, and intraoperative imaging of 
cancer-positive LNs and tumor margins during surgery. In preparation for the clinical 
evaluation of novel multimodal imaging agents, their team used an off-label, intradermal 
administration of ICG at microdoses to qualify their investigational, military-grade intensified 
charge-coupled device (CCD) camera in Phase I/II Investigational New Drug (IND) clinical 
studies [13,14]. “First-in-humans” targeting vectors under investigation at UTHSC consist of 
(i) a well-established peptide targeting the somatostatin receptor (SSTR) in neuroendocrine 
tumors (NETs) and (ii) affinity matured monoclonal antibodies (mAbs) or mAb-based 
fragments targeting epithelial cell adhesion molecule (EpCAM) [15,16], a protein almost 
universally overexpressed on the surface of cancer epithelial cells. Dual labeling strategies are 
based on innovative multimodality chelators which minimally affect the biological and 
pharmacokinetic (PK) properties of targeting agents. 
3. Navigational pathway 
Certain members from each of the NTR teams constituted the Chemistry Probes and Guided 
Therapies Core and have devised logical pathways for target identification (where applicable), 
design and synthesis of agents, production, batch release, validation, and subsequent 
deployment in both preclinical and investigational human studies (Fig. 1). 
 
Fig. 1. Pathways for developing and validating a molecular imaging agent (BD = 
biodistribution). 
Once beyond the agent discovery and development stages, the next three steps of 
synthesis, production, and batch release are defined strictly in a standard operating procedure 
(SOP). SOPs are critical for the subsequent translational phase wherein production steps and 
analytical assays for batch release are replicated, validated, and conducted under good 
laboratory practice (GLP) and typically include certificates of analysis for all reagents, 
calibration and maintenance logs for all equipment used, audit trails, and defined packaging 
and storage conditions that ensure validated stability. Examples of navigational pathways for 
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3.1. SU/VU agent development approach 
At SU, the focus has been on a single molecular probe, fluorocoxib (Fig. 2). The rationale for 
probe selection was to select a high-value imaging target that would have the greatest impact 
on early detection, guided resection, and prognosis, and to provide an outcome measure for a 
range of malignancies using a single molecule [17]. Based on the association of chronic 
inflammation with neoplasia and increased activity of the intracellular enzyme COX-2, the 
SU/VU collaboration identified several well-characterized COX-2 inhibitors as candidates for 
a molecularly target optical imaging agent. By employing various combinations of linkers and 
fluorophores during the agent synthesis process, they were able to generate a library of agents 
for subsequent evaluation. Since commercially available reagents and dyes may not always 
address specific needs for given molecule, the SU/VU collaboration provided the know-how 
to perform custom syntheses in-house and greatly enhanced the flexibility of agent design 
strategies. Ultimately, fluorocoxib was prepared by fluorescently labeling the COX-2 
inhibitor, indomethacin, and validated preclinically in vitro and in tumor-bearing animals. The 
in vivo imaging studies with fluorocoxib also allowed the investigators to define detection 
limits of the instrument as an added characterization step. By successfully demonstrating 
efficacy for tumor targeting with acceptable PK, the good manufacturing practice (GMP) 
synthesis, optimization of formulation, and toxicological testing were outsourced to a contract 
facility to complete the required preclinical characterization steps and initiate preparation of 
the IND application. 
 
Fig. 2. Screening and development of the COX-2 targeted agent, fluorocoxib by SU/VU. 
3.2. UM agent development approach 
For UM, the discovery process begins with target identification and peptide selection from 
screening phage libraries (Fig. 3). 
Solid phase synthesis with on-column fluorescent label conjugation enables precise 
labeling and composition that is characterized by mass spectrometry (MS), high-performance 
liquid chromatography (HPLC), and optical property measurements prior to being 
characterized for biological activity by a validated assay. If characterization of composition 
and biological activity meets a minimal, acceptable, but clearly defined criteria, the agent is 
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precisely formulated in its delivery vehicle before undergoing preclinical testing of efficacy 
with a designated imaging device. If successful, then the manufacturing plan is devised using 
GMP and the Chemistry, Manufacturing and Controls (CMC) section (which includes 
production, analytical testing, and batch release criteria) of an IND application is prepared. 
For a fluorescently labeled peptide such as that under development by UM, batch release  
 
Fig. 3. Flowchart for screening, selection, preparation, and characterization of fluorescent 
peptide probes at UM. 
criteria should include optical property measurements of extinction coefficient, fluorescent 
yield (quantum efficiency), and lifetime. Efficacy of resulting peptide agents are typically 
tested using scrambled or non-scrambled peptides in vitro as well as in vivo to establish 
potential utility and molecular specificity. 
3.3. WUSTL agent development approach 
Investigators at WUSTL have focused on translation of a clinical PAT device with off-label 
use of darkly colored dyes such as MB and ICG. PAT contrast is based on optical absorption 
and detection of ultrasound generation rather than fluorescence. Thus PAT enables detection 
of optical agents several centimeters below the skin surface. As a means of validating clinical 
PAT devices and pushing the boundaries of optical molecular imaging, WUSTL is also 
developing an array of agents that generate multiple contrast modes to combine optical 
imaging (PAT or Diffuse Optical Tomography (DOT)) with nuclear imaging (SPECT or 
Positron Emission Tomography (PET)). Isotopically labeled Iodine-125 MB may be used for 
whole-body SPECT/CT to validate SLN identification by PAT. Cypate, a functionalizable 
analog of ICG, possesses a high extinction coefficient for excellent PAT contrast as well as 
good quantum yield for fluorescence imaging. Conjugation of tyrosine for radio-iodination or 
a chelator for sequestration of radiometals enables combinations of PAT and DOT with 
SPECT (Indium-111) or PET (Copper-64). These agents provide non-specific lymph node 
mapping while other agents that are conjugated to targeting moieties will enable specificity to 
cancer. 
At the initial optical reporter discovery step depicted in Fig. 4, NIR reporters are sought 
due to the relative transparency of biological tissues in this light region and are needed to 
enable greatest tissue penetration and largest detectable PAT signal. Functionalizable NIR 
contrast agents with high absorption coefficients demonstrate a broad range of possibilities for 
molecular imaging contrast and potential for clinical applications of PAT. 
The development of the PAT dye with a functional group for conjugation to a chelator or 
targeting moiety is then decided. Whether using isotopic substitution or a chelated radiometal, 
radiolabeling of the final conjugate requires testing for labeling efficiency, radiochemical 
purity, and stability of the agent. Assessment of composition and possible alteration of optical 
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properties under the sometimes harsh radiolabeling conditions are then evaluated through 
HPLC, as well as measurement of optical properties. After formulation to the correct dosage, 
the in vivo efficacy of the probe is evaluated to assess the PK for reaching sentinel and 
subsequent LNs within the draining basin. If the agent provides adequate signal with a 
reasonable PK profile, it is then considered for further development, including stability 
testing, GMP production, GLP safety and toxicity testing, and eventually, investigational 
studies in humans. 
 
Fig. 4. Flowchart for synthesis and characterization multimodal agents for SLN mapping by 
WUSTL. 
3.4. UTHSC agent development approach 
The translational paradigm at UTHSC is twofold. First, the team engineers unique mAbs and 
mAb fragments with maximal affinity which contain chemical modifications to modulate PK 
and reactive groups introduced away from binding domain for site specific conjugation of a 
chelator, NIR fluorophore, or a customized multimodality chelator. In a second 
complementary approach, they conjugate a selected SSTR-targeting peptide with the 
multimodality chelator. As shown in Fig. 5, both cases choose the fluorophore on the basis of 
fluorescent properties, size, and stability in selected radiolabeling conditions, whether with 
Gallium-68 (t1/2 = 68 min) for rapidly clearing agents (e.g., peptides or mAb fragments), or 
Copper-64 (t1/2 = 12.7 h) for agents with longer circulation time (e.g., full-length mAbs). 
The resulting chelator, fluorophore, or multimodality chelator conjugate is then 
characterized by MS and HPLC, quantitative flow cytometry (for optical assessment), Lindmo 
assays (for radioactive assessment), or surface plasmon resonance (for quantifying biological 
activity on target expressing cells or target proteins themselves). If biological activity is 
quantitatively retained following conjugation(s), then optical properties, radiolabeling 
efficiency, and stability are determined before the product is deemed suitable for further 
evaluation. The product may then be lyophilized, frozen, or stored at 4°C for subsequent 
experiments. Next, in vivo studies are employed to determine if adequate signal is attainable at 
microdoses using clinically validated NIRF imaging instrumentation and a standardized PET 
imaging scanner [18]. Once validated in animal models, long-term stability testing, GMP 
production, GLP safety and toxicity testing are performed, and eventually, investigational 
human studies are conducted. It should be noted that the preclinical validation for mAbs 
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typically employ isotype mAbs and mAb fragments as well as mAb products which cross 
react with both human and mouse targets. 
The pathways taken for each team are different, depending upon the translational 
objectives, but each focuses upon qualification of the imaging agent on the basis of biological 
activity and imaging performance based upon the appropriate criteria (radiolabeling 
efficiency, fluorescent yield, absorption coefficient). Eventually, each approach arrives at a 
common point which where a GMP compliant manufacturing plan is required in order to gain 
approval for human studies. 
 
Fig. 5. Flowchart for preparation and characterization of fluorescent and dual-labeled mAbs by 
UTHSC. (D/P = dye/protein ratio, QC = quality control). 
4. Anticipate problems in translational research 
While these translational studies are underway, findings of potentially confounding 
difficulties have been, and will continue to be, encountered as progress is made toward the 
clinic. The uncertain pathway provides an additional impetus for our community to share 
common experiences that will in turn enable more efficient navigational routes for shared, 
effective translation strategies. The first most commonly encountered problem in translation 
of optical imaging agents is the lack of well-suited instrumentation, including analytical 
equipment that is operational in relevant wavelengths often in the NIR range. While this 
deficiency in analytical equipment is lessening with the widespread development and use of 
NIR fluorophores with low autofluorescent characteristics, common analytical instruments 
such as confocal microscopes, HPLCs, plate readers, flow cytometers, etc., typically require 
custom retrofitting with diodes, detectors, filters, and lenses with coatings that enable NIR 
interrogation. In addition, conventional endoscopy and intraoperative devices are being or 
have been adapted to image ICG, typically administered i.v. and detected at far larger doses 
than would be required for the pico- to femto-molar concentrations needed for molecular 
imaging. However, promising findings from preclinical research have revealed, in some 
applications, complementary data sets obtained with NIR and nuclear imaging [19–22]. 
Therefore, dual-labeled agents are rapidly being recognized as emerging clinical opportunities 
for multimodality validation and development of hybrid agents for diagnostic and 
intraoperative imaging [23–25]. It should be noted that Azhdarinia and associates showed that 
radiolabeling can alter the fluorescent properties of NIR fluorophores with varying degrees 
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based on the harshness of reaction conditions [26]. As a result, the process of choosing a 
fluorophore and optimizing radiolabeling conditions must be carefully conducted as indicated 
in the agent development flow charts above to ensure that the fluorescent optical properties of 
dual-labeled agents are comparable to a (single) fluorescently labeled counterpart. 
Another emerging difficulty relates to some of the companies that produce reagent-grade 
NIR dyes and have built their business on academic research. Besides the already restrictively 
high price for reagent-grade dyes, the requirements of increased pricing for GMP-produced 
dyes and “clinical trial agreements” that include intellectual property rights to optical imaging 
devices and technologies complicates the translation of NIR conjugates. Moreover, academic 
and industrial partners are likely unable to financially and legally agree to such an agreement 
making this practice selectively detrimental to the biomedical optics community. Given that 
GMP manufacturers of chelators for nuclear imaging do not exhibit the same level of 
involvement in the translational use of their reagents, the biomedical optics community may 
face significantly larger obstacles when compared to nuclear imaging. As the value 
proposition for optical imaging is realized, these relationships may be predicted to evolve and 
change rapidly. It is noteworthy that an increasing number of companies are manufacturing 
NIR fluorophores at reasonable costs, but not all provide chemical structures and identity 
information necessary for incorporation into CMC documentation. As an alternative strategy 
to overcome this translational barrier, academic centers could engage in the production of NIR 
fluorophores alone or in consortia of academic/industrial partners. Otherwise, it is never too 
early to initiate a discussion with the R&D department of a dye manufacturer if one intends to 
employ its dye in an imaging agent used in translational studies. 
Finally, due to the importance of demonstrating innovation in their individual research 
programs, academicians are constantly employing novel reagents, targeting molecules, 
chemical compositions, and formulations in their studies. While this accelerates innovation in 
the field, it reduces commonality and limits the ability to directly compare and cross-validate 
promising preclinical data which may have translational potential. Therefore, consensus 
efforts are critical and can add value to the field by identifying general schemes within which 
current probe development efforts can be grouped, while also proposing a navigational route 
to improve upon existing translational efforts. Academic researchers are not typically focused 
on the cumbersome manufacturing process of new imaging agents for clinical trials and may 
find themselves facing significant obstacles as promising imaging agents advance toward 
human testing. In particular, the development of reproducible and validated synthetic 
processes are lacking in academia. As the handoff to a contract manufacturer typically occurs 
for GMP manufacturing of a probe, the presence of validated SOPs, batch records, and 
analytical data are critical and can facilitate efficient method development and validation by a 
contract manufacturer. Accordingly, academic laboratories and consortia would benefit from 
developing detailed compound characterization checklists which include standard tests such 
as structural confirmation and purity of the probe, but also more extensive analyses of 
compound-specific criteria such (i) radiolabeling efficiency of dual-labeled probes, (ii) 
stability of i.v. vs. topical formulations, (iii) amenability to processing steps such as 
lyophilization, and (iv) effects of storage conditions. Highly rigorous testing in academic 
laboratories offers a better likelihood for cross-validation of methods by the outside 
manufacturer, and ultimately supports more efficient translational development of a probe. 
5. Conclusion and summary 
Due to the complexities associated with designing and characterizing a molecular imaging 
probe for human use, it is highly beneficial to the research community to share our 
experiences in obtaining the necessary know-how and resources to carry the translational 
process from beginning to end. Building upon the recent NTR-wide publication by Aldrich et 
al. that focused on instrument validation needs of each research team [27], this contribution 
stresses the importance of creating consensus efforts to bridge gaps that exist in the 
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understanding of the translational process specific to imaging agents. Under our model, there 
is constant interaction between the core and advisors in regulatory agencies as well as industry 
leaders that are well-versed in translation. Several prominent individuals from imaging-related 
pharmaceutical companies participate in defining research strategies and milestones for each 
research program to better obtain alignment with industry standards. The direct input is 
critical to the success of translating new imaging technologies into the clinic and forms the 
basis for the recommendations for best practices set forth by the core. Defining plans for 
probe development from the ground up will provide academicians with a more comprehensive 
understanding of factors such as milestones, timelines, and expected costs of clinical testing, 
which substantially improves the likelihood of success for translating new imaging 
technologies into humans. 
As alluded to in Section 4, market segmentation can profoundly influence whether a 
technology with diverse components can be clinically translated, irrespective of a compelling 
case for improved patient outcomes. In the current economic climate, collaborations which 
include these diverse markets are critical for a single, shared and focused mission of 
technology application for improved patient outcomes. For this case of biomedical optical 
imaging, the challenges of focusing the instrumentation and reagent industries on a shared 
mission is best met by roadmap objectives since translation and regulatory strategies will 
involve not one or the other, but both industries. The roadmap for translating biomedical 
optical imaging (both drug and device) requires assessing the shared translational routes for 
both instrumentation and reagent industries. Identifying the navigational routes for translating 
optical imaging agents and (under the charge of the Instrumentation Core working group of 
the NTR) optical imaging devices, enables a better understanding of how these industry 
segments can collaborate to realize a new markets to meet unmet clinical needs. 
Most importantly, the ability to bring diverse, segmented markets together requires not 
only a compelling clinical need, but a compelling market as well. The clinical “impact” of 
research and technology developments to solve unmet needs is judged as a criterion on most 
research grants. Yet “impact” is not always examined with the consideration of economic or 
market limitations as are “market assessments.” In addition, principles of beneficence require 
that we engage in clinical research that can benefit populations (whether orphan or not), and 
by interference, involve technologies that have either an existing or potential market (whether 
large or small). The navigational routes established for both optical imaging devices and 
imaging agents enable greater clarity for conducting market assessments that need to be 
continually updated along the overall route for translating optical imaging technologies. In 
this NTR Chemistry Probes and Guided Therapies Core working group, market assessments 
were not part of the general translational roadmap although they were made in varying 
degrees by each of the participating centers and partners for their entire technology platforms. 
Nonetheless, the clinical impact is significant for cancer patients and survivors who need 
image guidance for improved therapy and real-time risk assessment. As a community, we 
need to ensure that our discoveries that have clear evidence to fulfill unmet clinical needs 
actually translate into the clinic. We may need to pose our discoveries in the context of 
existing or new markets and educate both the clinical end-users and the patient population 
who can benefit from these advances. Given the number of unmet clinical needs that can be 
addressed using optical physics, and the advances in optical instrumentation, there is a bright 
future for biomedical optical imaging agents. 
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